Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hoechst 33258. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 3/20 | 0.78 |
| ▸ | TOP2A known ✓ | P11388 | 3/20 | 0.78 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.54 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.52 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.49 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.47 |
| ▸ | CDK4 known ✓ | P11802 | 1/20 | 0.46 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.54 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hoechst 33258 SCHEMBL5682613 | 1.00 | TOP1 (0.78) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD | |
| Hoechst 33258 SCHEMBL21847754 | 0.99 | ALDH1A1 (0.77) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD | |
| Hoechst 33258 SCHEMBL1439775 | 0.99 | TOP1 (0.79) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD | |
| Hoechst 33258 SCHEMBL617906 | 0.98 | ALDH1A1 (0.79) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD | |
| Hoechst 33258 SCHEMBL29350619 | 0.98 | ALDH1A1 (0.79) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD | |
| Hoechst 33258 SCHEMBL13856958 | 0.92 | ALDH1A1 (0.89) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD | |
| Hoechst 33258 SCHEMBL18089342 | 0.92 | ALDH1A1 (0.89) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD | |
| Hoechst 33258 SCHEMBL6942659 | 0.90 | ALDH1A1 (0.71) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD | |
| Hoechst 33258 SCHEMBL30597851 | 0.87 | TOP1 (1.00) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD | |
| Hoechst 33258 SCHEMBL29443416 | 0.87 | TOP1 (1.00) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3223816-B1 | METHODS FOR TREATING A CYTOMEGALOVIRUS INFECTION | THE J DAVID GLADSTONE INST (US) | 2020-04-22 | — | — | EP | claimed |
| US-10478431-B2 | Methods for treating a cytomegalovirus infection | THE J. DAVID GLADSTONE INSTITUTES (US) | 2019-11-19 | — | — | US | claimed |
| US-20170360778-A1 | Methods for Treating a Cytomegalovirus Infection | THE J. DAVID GLADSTONE INSTITUTES | 2017-12-21 | — | — | US | claimed |
| US-20170299482-A1 | COUNTERSTAINS FOR A BIOLOGICAL SAMPLE | DIAGNOSTIC BIOSYSTEMS (US) | 2017-10-19 | — | — | US | claimed |
| EP-3223816-A1 | METHODS FOR TREATING A CYTOMEGALOVIRUS INFECTION | The J. David Gladstone Institutes (US) | 2017-10-04 | — | — | EP | claimed |
| WO-2016086060-A1 | METHODS FOR TREATING A CYTOMEGALOVIRUS INFECTION | THE J. DAVID GLADSTONE INSTITUTES (US) | 2016-06-02 | — | — | WO | claimed |
| US-20260015668-A1 | COMPOSITION AND METHODS RELATED TO MODIFICATION OF 5 HYDROXYMETHYLCYTOSINE (5-hmC) | THE UNIVERSITY OF CHICAGO (US) | 2026-01-15 | — | — | US | disclosed |
| US-10718694-B2 | Counterstains for a biological sample | DIAGNOSTIC BIOSYSTEMS (US) | 2020-07-21 | — | — | US | disclosed |
| EP-3223816-B1 | METHODS FOR TREATING A CYTOMEGALOVIRUS INFECTION | THE J DAVID GLADSTONE INST (US) | 2020-04-22 | — | — | EP | disclosed |
| US-20200102616-A1 | COMPOSITION AND METHODS RELATED TO MODIFICATION OF 5 HYDROXYMETHYLCYTOSINE (5-hmC) | THE UNIVERSITY OF CHICAGO | 2020-04-02 | — | — | US | disclosed |
| US-10478431-B2 | Methods for treating a cytomegalovirus infection | THE J. DAVID GLADSTONE INSTITUTES (US) | 2019-11-19 | — | — | US | disclosed |
| US-20190290656-A1 | PT(IV) PRODRUGS | YISSUM RESEARCH DEVELOPMENT OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2019-09-26 | — | — | US | disclosed |
| EP-3397643-A1 | Pt(IV) PRODRUGS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2018-11-07 | — | — | EP | disclosed |
| US-20170360778-A1 | Methods for Treating a Cytomegalovirus Infection | THE J. DAVID GLADSTONE INSTITUTES | 2017-12-21 | — | — | US | disclosed |
| US-20170299482-A1 | COUNTERSTAINS FOR A BIOLOGICAL SAMPLE | DIAGNOSTIC BIOSYSTEMS (US) | 2017-10-19 | — | — | US | disclosed |
| EP-3223816-A1 | METHODS FOR TREATING A CYTOMEGALOVIRUS INFECTION | The J. David Gladstone Institutes (US) | 2017-10-04 | — | — | EP | disclosed |
| WO-2017115372-A1 | Pt(IV) PRODRUGS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-07-06 | — | — | WO | disclosed |
| WO-2016086060-A1 | METHODS FOR TREATING A CYTOMEGALOVIRUS INFECTION | THE J. DAVID GLADSTONE INSTITUTES (US) | 2016-06-02 | — | — | WO | disclosed |
| US-8741567-B2 | Composition and methods related to modification of 5-hydroxymethylcytosine (5-hmC) | THE UNIVERSITY OF CHICAGO (US) | 2014-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015668-A1 | COMPOSITION AND METHODS RELATED TO MODIFICATION OF 5 HYDROXYMETHYLCYTOSINE (5-hmC) | MTAP, PNP, NT5C3B | TOP1 307/4885TOP2A 870/4885GLA 1614/4885 |
| US-20190290656-A1 | PT(IV) PRODRUGS | TPI1, MPI, ERBB4 | TOP1 99/4885TOP2A 124/4885GLA 2950/4885 |
| US-10478431-B2 | Methods for treating a cytomegalovirus infection | MGMT, CMBL, PAICS | TOP1 210/4885TOP2A 295/4885GLA 1809/4885 |
| US-20170360778-A1 | Methods for Treating a Cytomegalovirus Infection | MGMT, CMBL, PAICS | TOP1 210/4885TOP2A 295/4885GLA 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.